FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175514571> ?p ?o ?g. }

• W3175514571 abstract "Allogeneic stem cell transplantation (allo-HSCT) is the ultimate cure for acute lymphoblastic leukemia (ALL).This study was performed to compare the outcomes of ALL patients receiving busulfan (Bu) with cyclophosphamide (Cy)-based or total body irradiation (TBI)-based regimen in a Chinese population.We enrolled 224 adult patients with ALL who received allo-HSCT at National Taiwan University Hospital between 1997 and 2016.The median age at transplantation was 33 years. Before allo-HSCT, 75.9% of patients attained first or late complete remission. A total of 141 patients (62.9%) received Bu/Cy-based conditioning, either myeloablative (MA) or reduced-intensity stem cell transplantation (RIST), and 83 patients received a TBI-based regimen (MA-TBI). Patients receiving the MA-Bu regimen had longer relapse-free survival (RFS) than those receiving the MA-TBI regimen (median, 24.1 vs. 6.7 months, p = .044). There was no difference in overall survival (OS, MA-Bu vs. MA-TBI vs. RIST-Bu: 39.4 vs. 28.2 vs. 13.1 months, p = .276), treatment-related mortality (TRM), or incidences of grade 3-4 acute graft-versus-host disease (GvHD). Among patients receiving identical GvHD prophylactic regimens, there was no difference between MA-Bu and MA-TBI groups regarding the incidence of grade 3-4 acute GvHD, grade 2-4, and all-grade chronic GvHD. In subgroup analysis, patients receiving oral busulfan had comparable RFS and OS to the intravenous busulfan group (p = .436 and p = .236, respectively), but a higher TRM (25% vs. 9.8%, p = .016). In the multivariable analysis, disease status before allo-HSCT was the only risk factor impacting RFS and OS.In summary, patients receiving Bu/Cy-based or TBI-based regimens as conditioning had similar results in terms of OS, TRM, and acute GvHD, whereas the use of myeloablative Bu/Cy resulted in a better RFS. A Bu-based regimen could be an alternative conditioning choice for patients who are ineligible to receive TBI. Prospective and randomized controlled trials are warranted to validate the long-term outcomes." @default.
• W3175514571 created "2021-07-05" @default.
• W3175514571 creator A5000152081 @default.
• W3175514571 creator A5007182076 @default.
• W3175514571 creator A5007548386 @default.
• W3175514571 creator A5010035183 @default.
• W3175514571 creator A5046684817 @default.
• W3175514571 creator A5068998494 @default.
• W3175514571 creator A5073227099 @default.
• W3175514571 creator A5080199901 @default.
• W3175514571 creator A5081299798 @default.
• W3175514571 date "2021-06-30" @default.
• W3175514571 modified "2023-10-16" @default.
• W3175514571 title "Busulfan‐containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study" @default.
• W3175514571 cites W1992011065 @default.
• W3175514571 cites W1993665924 @default.
• W3175514571 cites W1993783426 @default.
• W3175514571 cites W2012187988 @default.
• W3175514571 cites W2018956546 @default.
• W3175514571 cites W2035343180 @default.
• W3175514571 cites W2037148599 @default.
• W3175514571 cites W2042888665 @default.
• W3175514571 cites W2079167213 @default.
• W3175514571 cites W2086891287 @default.
• W3175514571 cites W2091001903 @default.
• W3175514571 cites W2094729406 @default.
• W3175514571 cites W2116478257 @default.
• W3175514571 cites W2118796952 @default.
• W3175514571 cites W2122652108 @default.
• W3175514571 cites W2182750712 @default.
• W3175514571 cites W2220712703 @default.
• W3175514571 cites W2269223862 @default.
• W3175514571 cites W2316285142 @default.
• W3175514571 cites W2339482838 @default.
• W3175514571 cites W2398243892 @default.
• W3175514571 cites W2398700149 @default.
• W3175514571 cites W2400439118 @default.
• W3175514571 cites W2419639370 @default.
• W3175514571 cites W2525939690 @default.
• W3175514571 cites W2529889366 @default.
• W3175514571 cites W2591709377 @default.
• W3175514571 cites W2774624088 @default.
• W3175514571 cites W2787621143 @default.
• W3175514571 cites W2803086223 @default.
• W3175514571 cites W2807317397 @default.
• W3175514571 cites W2889442370 @default.
• W3175514571 cites W2892758519 @default.
• W3175514571 cites W2908848053 @default.
• W3175514571 cites W2919051790 @default.
• W3175514571 cites W2931981435 @default.
• W3175514571 cites W2946567117 @default.
• W3175514571 cites W2965220174 @default.
• W3175514571 cites W3034343309 @default.
• W3175514571 cites W3175514571 @default.
• W3175514571 doi "https://doi.org/10.1002/cnr2.1488" @default.
• W3175514571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34196132" @default.
• W3175514571 hasPublicationYear "2021" @default.
• W3175514571 type Work @default.
• W3175514571 sameAs 3175514571 @default.
• W3175514571 citedByCount "2" @default.
• W3175514571 countsByYear W31755145712021 @default.
• W3175514571 countsByYear W31755145712023 @default.
• W3175514571 crossrefType "journal-article" @default.
• W3175514571 hasAuthorship W3175514571A5000152081 @default.
• W3175514571 hasAuthorship W3175514571A5007182076 @default.
• W3175514571 hasAuthorship W3175514571A5007548386 @default.
• W3175514571 hasAuthorship W3175514571A5010035183 @default.
• W3175514571 hasAuthorship W3175514571A5046684817 @default.
• W3175514571 hasAuthorship W3175514571A5068998494 @default.
• W3175514571 hasAuthorship W3175514571A5073227099 @default.
• W3175514571 hasAuthorship W3175514571A5080199901 @default.
• W3175514571 hasAuthorship W3175514571A5081299798 @default.
• W3175514571 hasBestOaLocation W31755145711 @default.
• W3175514571 hasConcept C126322002 @default.
• W3175514571 hasConcept C141071460 @default.
• W3175514571 hasConcept C2776694085 @default.
• W3175514571 hasConcept C2776755627 @default.
• W3175514571 hasConcept C2777408962 @default.
• W3175514571 hasConcept C2778880498 @default.
• W3175514571 hasConcept C2780611847 @default.
• W3175514571 hasConcept C2781413609 @default.
• W3175514571 hasConcept C2911091166 @default.
• W3175514571 hasConcept C71924100 @default.
• W3175514571 hasConcept C88879693 @default.
• W3175514571 hasConcept C90924648 @default.
• W3175514571 hasConceptScore W3175514571C126322002 @default.
• W3175514571 hasConceptScore W3175514571C141071460 @default.
• W3175514571 hasConceptScore W3175514571C2776694085 @default.
• W3175514571 hasConceptScore W3175514571C2776755627 @default.
• W3175514571 hasConceptScore W3175514571C2777408962 @default.
• W3175514571 hasConceptScore W3175514571C2778880498 @default.
• W3175514571 hasConceptScore W3175514571C2780611847 @default.
• W3175514571 hasConceptScore W3175514571C2781413609 @default.
• W3175514571 hasConceptScore W3175514571C2911091166 @default.
• W3175514571 hasConceptScore W3175514571C71924100 @default.
• W3175514571 hasConceptScore W3175514571C88879693 @default.
• W3175514571 hasConceptScore W3175514571C90924648 @default.
• W3175514571 hasIssue "3" @default.
• W3175514571 hasLocation W31755145711 @default.
• W3175514571 hasLocation W31755145712 @default.

• next